US4598078A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-(substituted piperazinyl) alkylbicyclic succinimide derivatives
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1983-10-19
•
Granted: 1986-07-01
•
Expires: 2003-10-19
Abstract
Abstract A succinimide derivative of the formula: ##STR1## wherein A is straight or branched C 2 -C 6 alkylene or alkenylene, B is straight or branched C 3 -C 5 alkylene, D is straight or branched C 2 -C 3 alkylene, E is straight or branched C 2 -C 3 alkylene, R 1 and R 2 are each hydrogen or C 1 -C 4 alkyl, or they may form a single bond and R 3 is a phenyl group optionally substituted with C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen and/or trifluoromethyl, a 2-pyridyl group optionally substituted with halogen, a 2-pyrimidyl group optionally substituted with halogen, a group of the formula: ##STR2## (in which R 4 is hydrogen or phenyl), a group of the formula: CO--R 5 (in which R 5 is adamantyl or furyl) or hydroxy (C 2 -C 4 ) alkyl, and an acid addition salt thereof, which are useful as anti-anxiety drugs and/or anti-allergic drugs.
Inventors
- 👤 Kikuo Ishizumi
- 👤 Fujio Antoku
- 👤 Yukio Asami
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:54
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/44; C07D209/48; A; A61; A61P; A61P25/00; A61P25/20; C07C; C07C51/00; C07C51/54; C07C51/567; C07C61/00; C07C61/08; C07C61/09; C07C61/16; C07C61/22; C07C61/24; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/32; C07D239/42; C07D295/00; C07D295/04; C07D295/06; C07D295/073; C07D401/00; C07D401/02; C07D401/12; C07D403/00; C07D403/02; C07D403/12; C07D403/14
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
151 words
A succinimide compound of the formula: ##STR6## wherein R 1 and R 2 are each hydrogen or C 1 -C 4 alkyl, or they may form a single bond; R 3 is a phenyl group, a phenyl group mono-substituted with C 1 -C 4 alkyl C 1 -C 4 alkoxy, halogen or trifluoromethyl, a 2-pyridyl group, a 2-pyridyl group mono-substitued with halogen, a 2-pyrimidyl group, a 2-pyrimidyl group mono-substituted with halogen, a group of the formula: ##STR7## (in which R 4 is hydrogen or phenyl), a group of the formula: CO--R 5 (in which R 5 is adamantyl or furyl) or hydroxy(C 2 -C 4 )alkyl; R 6 , R 7 , R 8 and R 9 are each hydrogen or methyl; n is an integer of 3 to 5; a full line accompanying a broken line ( ) indicates a single or double bond or an acid addition salt thereof.
Claim 2
Dependent Claim
151 words
A succinimide compound of the formula: ##STR6## wherein R 1 and R 2 are each hydrogen or C 1 -C 4 alkyl, or they may form a single bond; R 3 is a phenyl group, a phenyl group mono-substituted with C 1 -C 4 alkyl C 1 -C 4 alkoxy, halogen or trifluoromethyl, a 2-pyridyl group, a 2-pyridyl group mono-substitued with halogen, a 2-pyrimidyl group, a 2-pyrimidyl group mono-substituted with halogen, a group of the formula: ##STR7## (in which R 4 is hydrogen or phenyl), a group of the formula: CO--R 5 (in which R 5 is adamantyl or furyl) or hydroxy(C 2 -C 4 )alkyl; R 6 , R 7 , R 8 and R 9 are each hydrogen or methyl; n is an integer of 3 to 5; a full line accompanying a broken line ( ) indicates a single or double bond or an acid addition salt thereof.
Claim 3
Dependent Claim
81 words
The succinimide derivative as claimed in claim 1, which is a compound of the formula: ##STR8## wherein n is an integer of 3 to 5, R 7 is hydrogen or methyl and R 10 is a phenyl group, a phenyl group mono-substituted with C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen or trifluoromethyl, a 2-pyridiyl group, a 2-pyridiyl group mono-substituted with halogen, a pyrimidyl group, or a 2-pyrimidyl group mono-substituted with halogen, or an acid addition salt thereof.
Claim 4
Dependent Claim
16 words
The compound as claimed in claim 1, which is N-[4-{4-(2-pyrimidinyl)-1-piperazinyl}butyl]-4-cyclohexene-1,2dicarboximide or an acid addition salt thereof.
Claim 5
Dependent Claim
16 words
The compound as claimed in claim 1, which is N-[3-{4-(2-pyrimidinyl)-1-piperazinyl}propyl]cyclohexane-1,2-dicarboximide or an acid addition salt thereof.
Claim 6
Dependent Claim
16 words
The compound as claimed in claim 1, which is N-[4-{4-(2-pyrimidinyl)-1-piperazinyl}butyl]cyclohexane-1,2-dicarboximide or an acid addition salt thereof.
Claim 7
Dependent Claim
16 words
The compound as claimed in claim 1, wherein R 1 and R 2 are each hydrogen.
Claim 8
Dependent Claim
25 words
The compound as claimed in claim 1, wherein at least one of R 1 or R 2 is a C 1 -C 4 alkyl group.
Claim 9
Dependent Claim
33 words
The compound as claimed in claim 1, wherein R 3 is a phenyl group or a phenyl group mono-substituted with C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen or trifluoromethyl.
Claim 10
Dependent Claim
21 words
The compound as claimed in claim 1, wherein R 3 is a 2-pyridyl group or a 2-pyridyl group mono-substituted with halogen.
Claim 11
Dependent Claim
21 words
The compound as claimed in claim 1, wherein R 3 is a 2-pyrimidyl group or a 2-pyrimidyl group mono-substituted with halogen.
Claim 12
Dependent Claim
34 words
A pharmaceutical composition which comprises as an active ingredient a pharmaceutically effective amount of at least one of the compounds claimed in claim 1 and at least one pharmaceutically acceptable inert carrier or diluent.
Claim 13
Dependent Claim
19 words
The composition as recited in claim 11, which is in the form of a tablet, capsule, syrup or suspension.
Claim 14
Dependent Claim
18 words
The composition as recited in claim 11, which is in the form of an emulsion, solution or suspension.
Claim 15
Dependent Claim
15 words
The composition as recited in claim 11, which is in the form of a suppository.
Claim 16
Dependent Claim
28 words
A method for reducing anxiety or allergic activity which comprises administering an effective anti-anxious or antiallergic amount of the compound as recited in claim 1 to a mammal.
Claim 17
Dependent Claim
25 words
The method as recited in claim 15, wherein 1 to 500 mg of the succinimide is administered daily in a single dose or divided doses.
Claim 18
Dependent Claim
26 words
A method for reducing anxiety or allergic activity which comprises orally administering an effective anti-anxious or anti-allergic amount of the composition as recited in claim 12.
Claim 19
Dependent Claim
26 words
A method for reducing anxiety or allergic activity which comprises parenterally administering an effective anti-anxious or anti-allergic amount of the composition as recited in claim 13.
References Cited (Backward Citations)
US2343198A
Cited
US2672460A
Cited
US3084167A
Cited
US2904548A
Cited
US3198798A
Cited
US3362956A
Cited
US3398151A
Cited
US3472855A
Cited
US3541098A
Cited
US3579524A
Cited
US3917636A
Cited
US3717634A
Cited
US3907801A
Cited
US3850992A
Cited
FR2154520A1
Cited
US3976776A
Cited
US4182763A
Cited
US4261990A
Cited
GB2101590A
Cited
US4507303A
Cited
US4543355A
Cited
EP0109562A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-06-30 | 1989-12-30 | 1990-07-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-06-30 | 1993-12-30 | 1994-07-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-06-30 | 1997-12-30 | 1998-07-01 | $7700.00 | Window Closed / Lapsed |